Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05971628
Other study ID # APHP210351
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 2023
Est. completion date June 2029

Study information

Verified date June 2023
Source Assistance Publique - Hôpitaux de Paris
Contact Nicolas GOLSE, Doctor
Phone 3306 71 28 24 03
Email nicolas.golse@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a national, non-randomized, multicentric trial evaluating the feasibility and the tolerance of the RAPID procedure in patients with HCC with preserved liver function requiring a liver transplantation.


Description:

In France, the liver transplant allocation is based on the severity of liver failure, but patients with hepatocellular carcinoma (HCC) usually do not have hepatocellular failure, resulting in reduced access to liver transplantation. Two years after registration on the LT list, only 66% of those registered are transplanted due to tumor progression. This observation leads to the paradoxical conclusion that better access to transplantation is an absolute priority, but remains limited by the shortage of grafts. The split surgical of one graft into two grafts is the most effective way to increase the number of transplantable organs. This technique is performed daily as part of pediatric TH where the child receives the left lobe/liver, adapted to his morphology. However, in adults, transplantation of the left lobe (segments 2+3) or of the left liver (segments 2+3+4) associated with complete excision of the native liver generates a high rate of complications (small-for-size syndrome) and compromises graft and recipient survival. For these reasons, this type of procedure has been almost abandoned in France. One of the ways to increase the organ pool without risking liver failure is therefore to perform an auxiliary transplant with a partial graft from an organ harvested in its entirety and then shared. The investigators therefore wish to evaluate the feasibility and tolerance, the results and the "gain" of grafts after a standardized RAPID procedure ( Resection And Partial LIver Transplantation with Delayed Hepatectomy) allowing to transplant an adult with a left lobe (very small graft) from a shared whole graft (deceased donor in brain death) , and to compare the results with standard management (orthotopic HT with whole organ for HCC). The population is 50 major patients (in order to realize the RAPID procedure for 34 patients) with HCC requiring LT according to the usual transplantability criteria, with preserved liver function. The study lasts a maximum of 70 months (24 months of inclusion period, 6 months between selection and inclusion, <12 months between inclusion and the 1st RAPID time, 4 months maximum between the 2 RAPID Steps, 24 months of patient follow-up post 2nd step of RAPID). The study will proceed as described below : - Pre-selection, information and consent of the patient by the local team. - After validation by the scientific committee of the inclusion/exclusion criteria, the patient will be prioritized with the Biomedicine Agency (800 points at 6 months) - If necessary, he will receive a waiting treatment for the CHC - Step 1 of RAPID : During the first operation, he will have a left hepatectomy and then LT with a left lobe/liver in an orthotopic position. During this operation, a treatment (resection/destruction) of a possible HCC of the right liver can be proposed in order to not to leave active nodule(s). - Step 2 of RAPID : Within a maximum of 4 months, after graft hypertrophy, right hepatectomy of the remaining native liver will be realized. - The oncological and post-LT follow-up will then be no different from a standard out-of-protocol patient. Standard immunosuppression - At the end of the study, a comparative analysis will be made with the control group, the anonymous data of which will be transmitted by the ABM. The expected benefits for participants are : - Rapid access to LT thanks to prioritization by the Biomedicine Agency at 6 months. Moreover, prioritization on the list could make it possible to limit the use of waiting treatments (surgery, radiation therapy, chemoembolization, immunotherapy, etc.) with non-negligible side effects/morbidity (e.g. arterial dissection jeopardizing the future graft) and high costs. - reduction in the risk of leaving the list, of death on the list, - access to an excellent quality graft (strict donor selection criteria) while patients with HCC frequently receive marginal organs, known as "out of turn", in an attempt to reduce their wait, - possible improvement in intention-to-treat survival. The expected benefits for society are : - Overall increase in the organ pool = partial response to the shortage of organs from which all recipients will be able to benefit (reduction of waiting time), - reduction of costs related to waiting treatments in CHCs (patients registered on the list), - reduction of costs related to hospitalization in the event of acute decompensation of chronic liver disease (ACLF). The risks added by research : - The main risk is that caused by two successive interventions, close together. The international literature on orthotopic auxiliary grafting using a small graft shows that the morbidity is real but the medium and long-term results are good (4 postoperative deaths reported only). - The risk of small for size syndrome is not ruled out in the RAPID protocol but will be limited to a minimum by appropriate portal modulation measures, a surgical technique refined and implemented by the experience of each center + literature, and finally postoperative follow-up close.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date June 2029
Est. primary completion date October 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 68 Years
Eligibility Inclusion criteria (RAPID receiver) - 18 years = age = 68 years - Indication of LT for HCC validated in multidisciplinary meeting - AFP score = 2 (15) - Body mass index < 30 kg/m2 - MELD score = 15, without access to prioritization - PET CT-choline and PET CT-FDG without sign of extra-hepatic localizaton - Patient having been informed and able to give written consent to participate in the RAPID-HCC study - Validation of the patient's inclusion in the RAPID-HCC protocol by the scientific committee Exclusion criteria - History of, liver transplant, surgical or radiological portocaval anastomosis - History of major abdominal surgery (including hepatectomy) - History of abdominal radiotherapy (extrahepatic) - History of acute/chronic pancreatitis - Expected combined transplant - HCC located 1 cm away from the transection line required by the first stage hepatectomy - Portal or arterial thrombosis - patient with a pre-graft hepatic venous pressure gradient = 20mmHg - Ascites (clinical or radiological) less than 5 years ago - Hepatitis C viral load + - Acute or chronic hepatitis B (not cured) - HIV + serology - Severe comorbidities, in particular severe cardiovascular or respiratory or renal pathology (at the discretion of the medical-surgical team) - Patient on anticoagulant treatment - Patient who has received (or is due to receive) preoperative treatment with radioembolization on the right side, hepatectomy or radiotherapy near the hilum - Patient who received (or should receive) preoperative treatment with anti-tyrosine kinase (TKI) less than three months ago - Patients receiving or having received immunotherapy Donor selection criteria: - Brain-dead donor (no living donor) - 18 years = age = 65 years - Hepatic, vascular and biliary anatomy compatible with performing a split. Analysis entrusted to the team that will carry out the split, and based on the scanner of the donor (to be available on the Biomedicine Agency website) - Biological and hepatic assessment compatible with the realization of a split, in particular transaminases < 4 times the normal - Graft not assigned to a protocol requiring machine infusion. - Serology: anti-HBc negative, anti-HCV negative

Study Design


Intervention

Procedure:
RAPID procedure
RAPID procedure stands for Resection And Partial Liver Transplantation with Delayed Hepatectomy for hepatocellular carcinoma

Locations

Country Name City State
France AP-HP, Paul Brousse Hospital Villejuif

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patient with successful RAPID procedure Success of the procedure will be assessed as a patient :
who complete the 2 steps of the procedure,
who had no graft resection and who is still alive 4 months later.
4 months after the second RAPID step
Primary Tolerance of the RAPID procedure Tolerance will be assessed with Adverse events related to the procedure from first stage of the surgical protocol and until 90 days after the second stage
Secondary Proportion of grafts in place Number of patients with a graft in place at 4 months after the first surgical step 4 months after the first surgical step
Secondary Survival of grafts at 2 years from liver transplantation (LT) Survival RAPID grafts considered in the event of a graft still in place Non-survival in the event of the patient's death or new LT at 2 Years from LT
Secondary Survival of patient at 2 year after their registration on the waiting list of transplantation whatever the cause of death at 2 year after their registration on the waiting list of transplantation
Secondary Survival of patient at 2 year after LT at 2 year after LT
Secondary Incidence of rejection after RAPID Identification of histologically proven rejections within 2 years after the first stage of RAPID. at 2 years after the first stage of RAPID
Secondary Waiting time between listing on the waiting list and LT according to RAPID Time between registration the waiting list and TH according to RAPID (1st step) 1 year
Secondary Gain of grafts Number of left lobes transplanted according to RAPID protocol - the number of retransplantations = organ gain obtained. Will be also analysed, the number of right livers generated and transplanted, as well as the number of complete RAPID procedures (native liver excision) will also be analyzed. 70 months
Secondary Comparison of the drop-out rate between RAPID group and control group Drop out will be estimated by exclusion from the LT program, whatever the cause : death, worsening, transplant refusal, etc. 18 months
Secondary Comparison of the waiting time between registration on the transplantation list and LT between RAPID group and control group Patients who completed the 1st RAPID phase compared to the control group up to 18 months
Secondary Comparison of the graft survival at 2 years after LT between RAPID group and control group at 2 years after 1rst stage of RAPID
See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Completed NCT03963206 - Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) Phase 4
Completed NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT05263830 - Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Recruiting NCT05095519 - Hepatocellular Carcinoma Imaging Using PSMA PET/CT Phase 2
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Completed NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Active, not recruiting NCT04039607 - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3
Terminated NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2